JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Gesloten

SectorGezondheidszorg

3.55 -3.27

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.51

Max

3.69

Belangrijke statistieken

By Trading Economics

Inkomsten

-15M

-40M

Verkoop

8.2M

50M

Winstmarge

-80.43

Werknemers

435

EBITDA

-19M

-42M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+8.7% upside

Dividenden

By Dow Jones

Volgende Winsten

7 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

206M

1.3B

Vorige openingsprijs

6.82

Vorige sluitingsprijs

3.55

Nieuwssentiment

By Acuity

50%

50%

177 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 apr 2026, 23:33 UTC

Populaire aandelen

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 apr 2026, 23:24 UTC

Winsten

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 apr 2026, 23:15 UTC

Belangrijke Nieuwsgebeurtenissen

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 apr 2026, 22:46 UTC

Winsten

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 apr 2026, 22:37 UTC

Winsten

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 apr 2026, 22:15 UTC

Winsten
Belangrijke Nieuwsgebeurtenissen

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 apr 2026, 23:33 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 apr 2026, 23:31 UTC

Winsten

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 apr 2026, 23:31 UTC

Winsten

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 apr 2026, 23:30 UTC

Winsten

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 apr 2026, 23:30 UTC

Winsten

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 apr 2026, 23:19 UTC

Marktinformatie
Winsten

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 apr 2026, 23:09 UTC

Winsten

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 apr 2026, 23:03 UTC

Marktinformatie

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 apr 2026, 22:51 UTC

Winsten

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 apr 2026, 22:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

28 apr 2026, 22:48 UTC

Marktinformatie

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 apr 2026, 22:40 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 apr 2026, 22:32 UTC

Winsten

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 apr 2026, 22:25 UTC

Acquisities, Fusies, Overnames

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 apr 2026, 22:22 UTC

Winsten

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 apr 2026, 22:17 UTC

Marktinformatie

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 apr 2026, 22:14 UTC

Winsten

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 apr 2026, 22:14 UTC

Winsten

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 apr 2026, 22:07 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

8.7% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD  8.7%

Hoogste 5 USD

Laagste 3 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technische score

By Trading Central

2.02 / 2.115Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

177 / 348 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat